- Home
- BYFC vs ANL Comparison
BYFC vs ANL Comparison
Compare BYFC & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYFC
- ANL
- Stock Information
- Founded
- BYFC 1946
- ANL 2004
- Country
- BYFC United States
- ANL Cayman Islands
- Employees
- BYFC N/A
- ANL N/A
- Industry
- BYFC Savings Institutions
- ANL
- Sector
- BYFC Finance
- ANL
- Exchange
- BYFC Nasdaq
- ANL Nasdaq
- Market Cap
- BYFC 70.3M
- ANL 61.8M
- IPO Year
- BYFC 1996
- ANL 2023
- Fundamental
- Price
- BYFC $7.31
- ANL $1.64
- Analyst Decision
- BYFC
- ANL Hold
- Analyst Count
- BYFC 0
- ANL 1
- Target Price
- BYFC N/A
- ANL N/A
- AVG Volume (30 Days)
- BYFC 5.9K
- ANL 9.0K
- Earning Date
- BYFC 07-31-2025
- ANL 09-02-2025
- Dividend Yield
- BYFC N/A
- ANL N/A
- EPS Growth
- BYFC N/A
- ANL N/A
- EPS
- BYFC N/A
- ANL N/A
- Revenue
- BYFC $33,412,000.00
- ANL N/A
- Revenue This Year
- BYFC N/A
- ANL N/A
- Revenue Next Year
- BYFC N/A
- ANL N/A
- P/E Ratio
- BYFC N/A
- ANL N/A
- Revenue Growth
- BYFC N/A
- ANL N/A
- 52 Week Low
- BYFC $5.71
- ANL $1.10
- 52 Week High
- BYFC $9.46
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- BYFC 37.34
- ANL 55.77
- Support Level
- BYFC $7.26
- ANL $1.50
- Resistance Level
- BYFC $8.20
- ANL $1.99
- Average True Range (ATR)
- BYFC 0.10
- ANL 0.15
- MACD
- BYFC -0.10
- ANL 0.01
- Stochastic Oscillator
- BYFC 5.32
- ANL 43.82
About BYFC Broadway Financial Corporation
Broadway Financial Corp is active in the financial services domain. It is a savings and loan holding company in the United States. The Bank's business consists of deposits from the general public and using such deposits, together with borrowings and other funds, to make mortgage loans secured by residential properties and commercial real estate. Its deposits consist of passbook savings accounts, checking accounts, and negotiable order of withdrawal accounts, money market accounts and fixed-term certificates of deposit. The revenue is derived from interest income on loans and investments.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.